Management team

Kostas Alevizopoulos, PhD | Chief Executive Officer

Dr. Kostas Alevizopoulos is Chief Executive Officer of APIM Therapeutics and has more than 25 years of international experience in biotechnology, oncology drug development and life science innovation. He has held senior executive and R&D leadership positions in biotechnology and pharmaceutical companies across Europe, leading the development of therapeutics, medical devices and diagnostics from discovery through clinical development.

Before joining APIM Therapeutics, Dr. Alevizopoulos served in executive leadership roles including CEO of Medexis SA, Head of R&D at Apotech SA and Head of Preclinical R&D at Coegin Pharma. He is also a Partner at Ventac Partners, where he supports the development and financing of innovative life science companies.

Dr. Alevizopoulos has extensive expertise in oncology, peptide therapeutics, translational research, intellectual property and business development. Throughout his career he has successfully led multidisciplinary development programs, secured public and private funding, established international collaborations and managed global networks of CROs, CMOs and academic partners.

He holds a PhD in Molecular Biology from the University of Lausanne and has authored more than 40 peer-reviewed publications and numerous international patents.

Marit Otterlei, PhD | Chief Scientific Officer

Dr. Marit Otterlei is a Professor at the Department of Cancer Research and Molecular Medicine at the Faculty of Medicine, Norwegian University of Science and Technology (NTNU). Prof. Otterlei’s main focus in research is on proper function of biological processes, including DNA replication and repair. Prof. Otterlei has more than 90 peer reviewed international papers within the field including several review papers. She is a member of the Royal Norwegian Society of Science and Letter, 2006.

Dr. Otterlei received her M.Sc. in Chemistry in 1988 at the Norwegian Institute of Technology followed by a PhD degree in 1993 at the Institute of Cancer Research at the University of Trondheim. Dr. Otterlei was visiting scientist at Trancel Corporation, Santa Ana and Pancreas Transplant research, in Los Angeles, California, from 1990 through 1991. This position was followed by a Post.doc post at the Unigen Center for Molecular Biology at NTNU from 1994 through 1997. Dr. Otterlei became researcher and assistant professor at the institute of Cancer Research and Molecular Biology at NTNU in 1999, and stayed in this position until 2001, when she became visiting scientist at the Laboratory of Molecular Gerontology, National Institute of Aging, NIH, USA. Dr. Otterlei became Professor in medicine (molecular biology/molecular medicine) at the Department of Cancer Research and Molecular Medicine at NTNU in 2003.

Prof. Otterlei is a frequent presenter at international conferences. Besides the status as primary inventor of APIM, she brings extensive experience in the field of molecular understanding within the area to the company's board. Prof. Otterlei is a frequent presenter at international conferences. Besides the status as primary inventor of APIM, she brings extensive experience in the field of molecular understanding within the area to the company's board. For more information on Prf. Otterlei’s activities, please see her Publications.

Hans Olav Minsås, MBA. | Chief Financial Officer

Hans Olav Minsås is a business executive with more than 15 years experience in the financial sector. With an expertise on investment appraisal, financial analysis, accounting and financial management, Mr. Minsås fulfills the role of Chief Financial Officer within APIM Therapeutics advising the company on various financial matters. Prior to his employment in APIM Therapeutics, Hans Olav Minsås served as an Analyst at Impello, Spare Bank 1 and an Auditor, Financial Services at KPMG.

Hans Olav Minsås is a graduate and holder of a Masters degree in Business Administration (MBA) from the Norwegian School of Economics.